Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy

The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected by enzyme-linked immunosorbent assay. The secreted level of CD166 with radio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Huan, Chen, Ze-Tan, Zhu, Xiao-Dong, Li, Ling, Qu, Song, Wei, Zhao, Su, Fang, Wei, Jing-Ni, Liang, Zhong-Guo, Mo, Qi-Yan, Wu, Jiang-Bo, Meng, Hui-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609886/
https://www.ncbi.nlm.nih.gov/pubmed/28968954
http://dx.doi.org/10.18632/oncotarget.16399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609886/
https://www.ncbi.nlm.nih.gov/pubmed/28968954
http://dx.doi.org/10.18632/oncotarget.16399

Ejemplares similares